Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma

Published:2022-05-10 Issue:4 Volume:40 Page:596-608
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Li Miaomiao¹,Yu Hui¹,Qi Fei¹,Ye Yingying¹,Hu Dingyao¹,Cao Jiaowu¹,Wang Dedao¹,Mi Lan¹,Wang Zhengyi²,Ding Ning¹,Ping Lingyan¹,Shu Shaokun³,Zhu Jun¹^ORCID

Affiliation:

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Lymphoma Peking University Cancer Hospital & Institute Beijing China

2. I‐Mab Biopharma Shanghai China

3. Department of Biomedical Engineering Peking University Beijing China

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3009

Reference42 articles.

1. The non-Hodgkin lymphomas: A review of the epidemiologic literature

2. Current trends in large cell lymphoma

3. Diffuse Large B-Cell Lymphoma

4. Diffuse large B-cell lymphoma—treatment approaches in the molecular era

5. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma;Cancer Letters;2024-08

2. Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia;Leukemia Research;2024-08

3. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

4. Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy;Genes & Diseases;2024-01

5. The cross-talk between macrophages and tumor cells as a target for cancer treatment;Frontiers in Oncology;2023-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3